In each case, a high ENR program was linked to shorter tumor control with AR targeting, and there was a strong suggestion this program was not only prognostic but also predictive of failure to respond to AR targeting with enza or other ARPIs such as abiraterone or ADT alone. The gene discussed is AR; the disease is neoplasm.